Asceneuron SA

Asceneuron develops effective therapeutics for orphan tauopathies such as progressive supranuclear palsy (PSP) and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases. Our first candidate molecule for progressive supranuclear palsy is aimed at preventing the formation of toxic tau aggregates by a groundbreaking molecular mechanism and has the potential to enter Phase 1 clinical trials by mid-2015.